Biomarkers in alzheimer's disease: Not yet surrogate endpoints

Annals of the New York Academy of Sciences

Volumn 1180, Issue , 2009, Pages 119-124

  Coley, N ^a,b,c   Andrieu, S ^a,b,c   Delrieu, J ^c   Voisin, T ^a,c   Vellas, B ^a,c  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Biomarker; Clinical trials; Disease modifying trials; Surrogate endpoint

Indexed keywords

ALZHEIMER DISEASE VACCINE; ALZHEIMID; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; HOMOTAURINE; LY 2062430; MONOCLONAL ANTIBODY; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; SOLANEZUMAB; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; HUMAN; IMMUNIZATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA; VALIDATION PROCESS;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS;

EID: 70449427725     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04947.x     Document Type: Conference Paper

References (24)

1. Lovestone, S. & M. Thambisetty. 2009. Biomarkers for Alzheimer's disease trials-biomarkers for what? A discussion paper. J. Nutr. Health Aging 13: 334-336.
2. Blennow, K. & H. Zetterberg. 2009. Use of CSF biomarkers in Alzheimer's disease clinical trials. J. Nutr. Health Aging 13: 358-361.
3. Thomas, R.G., J.D. Berg, M. Sano & L. Thal. 2000. Analysis of longitudinal data in an Alzheimer's disease clinical trial. Stat Med. 19: 1433-1440.
4. Vellas, B., S. Andrieu, C. Sampaio, et al. 2008. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 7: 436-450.
5. Aisen, P.S. 2009. Interpreting biomarker data in therapeutic trials. J. Nutr. Health Aging 13: 337-338.
6. Gispen-de Wied, C., M. Kritsidima & A. Elferink. 2009. The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES). J. Nutr.Health Aging 13: 376-387.
7. Vellas, B., S. Andrieu, C. Sampaio & G. Wilcock. 2007. Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 6: 56-62.
8. EMEA. Committee for Medicinal Products for Human Use (CHMP). 2008. Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. CPMP/EWP/553/95 95 Rev. 1.
9. Siemers, E.R. 2009. How can we recognize "disease modification" effects? J. Nutr. Health Aging 13: 341-343.
10. Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69: 89-95.
11. Saumier, D., P.S. Aisen, S. Gauthier, et al. 2009. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the AlzhemedTM (Tramiprosate) experience. J. Nutr. Health Aging 13: 370-372.
12. Jack, C.R., Jr., M.M. Shiung, J.L. Gunter, et al. 2004. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62: 591-600.
13. Schott, J.M., S.L. Price, C. Frost, et al. 2005. Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology 65: 119-124.
14. Fox, N.C., R.S. Black, S. Gilman, et al. 2005. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64: 1563-1572.
15. Fox, N.C. & J. Kenedy. 2009. Structural imaging markers for therapeutic trials in Alzheimer's disease. J. Nutr. Health Aging 13: 350-352.
16. Van Der Flier, W.M. & P. Scheltens. 2009. Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data. J. Nutr. Health Aging 13: 353-355.
17. Nordberg, A. 2009. Molecular imaging markers in clinical trials in Alzheimer's disease. J. Nutr. Health Aging 13: 346-347.
18. Wischik, C. & R. Staff. 2009. Challenges in the conduct of disease-modifying trials in AD: practical experience from a Phase 2 trial of tau-aggregation inhibitor therapy. J. Nutr. Health Aging 13: 367-369.
19. Jobst, K.A., A.D. Smith, C.S. Barker, et al. 1992. Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 55: 190-194.
20. Wischik, C.M., P. Bentham, D.J.Wischik & K.Meng Seng. 2008. Tau aggregation inhibitor (TAI) therapy with rember TM arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimer's Dementia 4(Suppl 2): T167.
21. Lannfelt, L., K. Blennow, H. Zetterberg, et al. 2008. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a Phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7: 779-786.
22. Siemers, E.R., S. Friedrich, R.A. Dean, et al. 2008. Safety, tolerability and biomarker effects of an Aâ monoclonal antibody administered to patients with Alzheimer's disease. Alzheimer's Dementia 4(Suppl 2): T774.
23. Gilman S, Koller M, Black RS, et al. 2005. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562.
24. Lassere,M.N. 2008.The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat. Methods Med. Res. 17: 303-340.